Drug intelligence / Profile preview

Oligopinn

Development stage
Unknown
Lead developer
INNventa Pharm
Administration
Oral
01

Overview

Oligopinn is an oral dietary supplement developed by INNventa Pharm, specifically positioned for cardiovascular health. The product contains a standardized extract of French maritime pine bark (*Pinus pinaster*), which is rich in oligomeric proanthocyanidins (OPCs). Oligopinn is marketed to support microcirculation, maintain healthy blood pressure levels, and provide antioxidant protection. Its mechanism of action involves the stimulation of nitric oxide synthase, which increases the production of nitric oxide to facilitate vasodilation and improve endothelial function. Additionally, the extract exhibits anti-inflammatory properties by inhibiting pro-inflammatory mediators such as NF-kappaB and COX-2, and acts as a scavenger of reactive oxygen species to mitigate oxidative stress.

Brand names
Oligopinn
Other names
French maritime pine bark extractPinus pinaster extract
02

Targets

NOS1 (nNOS)NF-κBPTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Oligopinn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oligopinn.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call